B · Normal
[Eli Lilly: The targeted anti-cancer drug Olomorasib shows durable activity in first-line non-small cell lung cancer] On October 25, Eli Lilly stated that the targeted anti-cancer drug Olomorasib showed durable activity in first-line non-small cell lung cancer (NSCLC), and it is expected to obtain phase 3 NSCLC data from the SUNRAY-01 trial in the first half of 2027.
monoclonal antibody 🕐 2026-10-25 15:48
#cell #monoclonal antibody #U.S. stock trends #medicine #Pharmaceutical business
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

On October 26, Jefferies raised its target price for Apple from $263.66 to $270. 10-26 12:53 [Kelun Pharmaceutical Subsidiaries Announced Multiple Innovative Drug Research R 10-26 12:29 [Most of the main domestic futures contracts rose, with methanol and asphalt ris 10-26 11:36 [AbbVie: Icritumumab Injection Launched in China] On October 26, AbbVie announce 10-26 10:23 [Apple customer service responds to “iPhone Duo breaks in some channels”: Prices 10-26 10:07 [Ascletis Pharmaceuticals: A new drug clinical trial application for ASC39 oral 10-26 08:21

Comments

0/500
Captcha (click to refresh)
No comments yet